John Kuruvilla, MD on A New Standard in Phase II Study of Pembrolizumab vs. Brentuximab #ASCO2020 @ClevelandClinic #ASCO

John Kuruvilla, MD on A New Standard in Phase II Study of Pembrolizumab vs. Brentuximab #ASCO2020 @ClevelandClinic #ASCO

Cancer-News

1 month
2 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
John Kuruvilla, MD of Cleveland Clinic @ClevelandClinic discusses KEYNOTE-204: a randomized, open-label, phase III study of pembrolizumab vs. brentuximab vedotin in relapsed or refractory classic hodgkin lymphoma (R/R cHL)
Up Next Autoplay